4. Supporting professional services. Lin-gang Special Area supports the construction of R&D outsourcing and service centers and encourages them to provide enterprises in Lin-gang Special Area with professional biomedical R&D and production services. A subsidy equal to 10 percent of the confirmed actual service price is offered with a maximum of 5 million yuan each enterprise each year.

5. Supporting improvement in innovative drug R&D capability. Enterprises that hold new drug clinical approvals, drug production approvals and drug marketing licenses will be given a one-off subsidy of 3 million yuan for each approval/license. A maximum subsidy of 2 million yuan will be offered for each redeveloped existing drug with new indications. The total subsidy is 10 million yuan maximum for each enterprise each year.

6. Supporting R&D of medical devices. Enterprises that hold medical device registration certificates and medical device production licenses will be given a one-off subsidy of 2 million yuan for each certificate/license, with a maximum of 5 million for each enterprise each year.

7. Supporting application for professional certifications. Enterprises that have earned international and domestic professional certifications in the biomedical field will be given a one-off subsidy of 1 million yuan for each certification with a maximum of 5 million yuan each enterprise each year.

8. Supporting commissioned production. For drug marketing license holders that commission biomedical enterprises registered and settling sales tax in Lin-gang Special Area to produce their products, a reward equal to 1 percent of the annual increase in product sales will be offered with a maximum of 5 million yuan each year.

9. Supporting green development:

1) Micro/small biomedical R&D projects in incubation that rent premises for R&D are not required to conduct individual environmental impact assessments in principle, if the premises owner is qualified to conduct and file an environmental impact assessment. If the premises owner is not qualified to conduct and file an environmental impact assessment, after obtaining a project's environmental impact assessment approval and completing project acceptance and filing, the enterprises will be offered an subsidy equal to 100 percent (maximum) of the environmental impact assessment cost with a maximum of 50,000 yuan for each project.

2) Biomedical R&D enterprises that carry out standard collection, classification, temporary storage and disposal of hazardous waste and produce no more than 5 tons of hazardous waste a year will be given 100 percent financial support for hazardous waste disposal with a maximum of 100,000 yuan for each enterprise each year.

10. Other available supportive measures. Biomedical enterprises or institutions in Lin-gang Special Area will be included and classified in a database to enable precise policy implementation, priority support and combined support according to the actual situation of each enterprise and project. A professional service team will be set up to assist enterprises or institutions in the database in applying for State-level, Shanghai municipal or Lin-gang Special Area supportive policies for various resources (including improving land use efficiency, etc.), finance and taxation (including income tax, investment and financing, listing incentives, etc.), investment promotion and enterprise introduction (including enterprise settlement, headquarters economy, etc.), human resources (including talent introduction, training, housing [rental] subsidy, medical insurance, children's schooling, other incentives and subsidies, etc.), industrial progress (including breakthroughs in key core technologies and products, industrial capacity improvement, etc.), production-education integration (including industry-university-research cooperation, skilled personnel training, etc.), scientific and technological innovation (including functional platforms, IP facilitation services, R&D subsidies and incentives, etc.), whole process under bond, import and export facilitation for R&D goods, cross-border data flow, and subsidies for R&D premises.

This English version is only for reference. To learn more, please refer to the authoritative Chinese version.